InsiderClue
Stocks · Health care · Pharmaceutical Preparations

GENELUX Corp

GNLX Clue Score24
United States Fiscal year ends December CIK 0001231457
$2.56 +2.40% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $2.56 −89.24% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 26 Jan 2023. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2022Revenue11.1Operating income−3.0Net income−5.2EPS, diluted−0.57Fiscal year 2023Revenue0.2 −98.5%Operating income−24.2Net income−28.3EPS, diluted−1.16Fiscal year 2024Revenue0.0 −95.3%Operating income−31.7Net income−29.9EPS, diluted−0.95Fiscal year 2025Revenue0.0 +0.0%Operating income−33.2Net income−32.1EPS, diluted−0.86
FY2022FY2023FY2024FY2025
Revenue 11.1 0.2 0.0 0.0
Growth −98.5% −95.3% +0.0%
Operating income −3.0 −24.2 −31.7 −33.2
Net income −5.2 −28.3 −29.9 −32.1
Growth
EPS, diluted −0.57 −1.16 −0.95 −0.86

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2022Operating margin−27.2%Net margin−47.0%Free cash flow margin−32.7%Fiscal year 2023Operating margin−14,214.7%Net margin−16,645.3%Free cash flow margin−12,529.4%Fiscal year 2024Operating margin−396,200.0%Net margin−373,362.5%Free cash flow margin−270,112.5%Fiscal year 2025Operating margin−415,175.0%Net margin−401,812.5%Free cash flow margin−329,575.0%
FY2022FY2023FY2024FY2025
Operating margin −27.2% −14,214.7% −396,200.0% −415,175.0%
Net margin −47.0% −16,645.3% −373,362.5% −401,812.5%
Free cash flow margin −32.7% −12,529.4% −270,112.5% −329,575.0%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2022Operating cash flow−3.6Capital expenditure−0.0Free cash flow−3.6Fiscal year 2023Operating cash flow−20.3Capital expenditure−1.0Free cash flow−21.3Fiscal year 2024Operating cash flow−21.2Capital expenditure−0.4Free cash flow−21.6Fiscal year 2025Operating cash flow−25.3Capital expenditure−1.1Free cash flow−26.4
FY2022FY2023FY2024FY2025
Operating cash flow −3.6 −20.3 −21.2 −25.3
Capital expenditure −0.0 −1.0 −0.4 −1.1
Free cash flow −3.6 −21.3 −21.6 −26.4
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Cash0.4Shareholders’ equity−35.8Fiscal year 2023Cash9.4Shareholders’ equity19.5Fiscal year 2024Cash8.6Shareholders’ equity26.3Fiscal year 2025Cash5.3Shareholders’ equity11.5
FY2022FY2023FY2024FY2025
Cash 0.4 9.4 8.6 5.3
Shareholders’ equity −35.8 19.5 26.3 11.5

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
−27.2% −14,214.7% −396,200.0% −415,175.0%
−47.0% −16,645.3% −373,362.5% −401,812.5%
−32.7% −12,529.4% −270,112.5% −329,575.0%
Spending
82.0% 7,510.0% 237,475.0% 248,137.5%
45.2% 6,804.7% 158,825.0% 167,137.5%
0.4% 602.9% 4,762.5% 13,725.0%
Returns
n/a −145.3% −113.7% −278.5%
−94.1% −101.4% −86.0% −168.9%
Balance and payout
747.0% 30.2% 24.3% 39.3%